ASO Author Reflections: Oncotype DX RS Complementing the Prognostic Stage in the Updated AJCC 8th Edition for T1-2N1M0 ER-Positive HER2-Negative Breast Cancer

被引：1
|
作者：
Wang, Maoli [1 ]
Wu, Kejin [1 ]
Chen, Hongliang [1 ]
机构：
[1] Fudan Univ, Dept Breast Surg, Obstet & Gynecol Hosp, Shanghai, Peoples R China
来源：
ANNALS OF SURGICAL ONCOLOGY | 2019年 / 26卷 / 05期
关键词：
21-GENE RECURRENCE SCORE;
D O I：
10.1245/s10434-019-07198-x
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1236 / 1237
页数：2
相关论文
共 50 条
  • [1] ASO Author Reflections: Oncotype DX RS Complementing the Prognostic Stage in the Updated AJCC 8th Edition for T1-2N1M0 ER-Positive HER2-Negative Breast Cancer
    Maoli Wang
    Kejin Wu
    Hongliang Chen
    [J]. Annals of Surgical Oncology, 2019, 26 : 1236 - 1237
  • [2] The significance of Oncotype DX recurrence score in T1-2N1M0 ER positive HER2 negative breast cancer: An analysis combined with the prognostic stage in the updated AJCC 8th edition
    Chen, H.
    Wang, M.
    Zhang, P.
    Zhang, M.
    Wu, K.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [3] The Prognostic Significance of the Oncotype DX Recurrence Score in T1-2N1M0 Estrogen Receptor-Positive HER2-Negative Breast Cancer Based on the Prognostic Stage in the Updated AJCC 8th Edition
    Wang, Maoli
    Wu, Kejin
    Zhang, Peng
    Zhang, Mingdi
    Ding, Ang
    Chen, Hongliang
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (05) : 1227 - 1235
  • [4] The Prognostic Significance of the Oncotype DX Recurrence Score in T1-2N1M0 Estrogen Receptor-Positive HER2-Negative Breast Cancer Based on the Prognostic Stage in the Updated AJCC 8th Edition
    Maoli Wang
    Kejin Wu
    Peng Zhang
    Mingdi Zhang
    Ang Ding
    Hongliang Chen
    [J]. Annals of Surgical Oncology, 2019, 26 : 1227 - 1235
  • [5] Prognosic Stage Groups Established by AJCC Staging System 8th Edition May Help to Individualize Postmastectomy Radiation Therapy in T1-2N1M0 Breast Cancer
    Wang, S.
    Sun, G. Y.
    Tang, Y.
    Jin, J.
    Liu, Y. P.
    Song, Y. W.
    Wang, W. H.
    Fang, H.
    Ren, H.
    Liu, X. F.
    Yu, Z. H.
    Li, Y.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E53 - E54
  • [6] The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center
    Thibodeau, Stephane
    Voutsadakis, Ioannis A.
    [J]. EUROPEAN JOURNAL OF BREAST HEALTH, 2019, 15 (03) : 163 - 170
  • [7] Evaluation of the AJCC 8th staging system in patients with T1-2N0M0, estrogen receptor-positive, HER2-negative invasive breast cancer: a population-based analysis
    Ding, S.
    Zhu, L.
    Wu, J.
    Lin, C.
    Andriani, L.
    Goh, C.
    [J]. BREAST, 2019, 44 : S89 - S89
  • [8] Comparison of predicted benefit using RS clin versus observed benefit in a US registry of stage I ER-positive HER2-negative high oncotype DX RS breast cancer.
    Walden, Christopher David
    Mosiman, Samuel
    Borgert, Andrew J.
    Parsons, Benjamin Marshall
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Discordant classification and outcomes between Prosigna and Oncotype Dx Recurrence Score for ER-positive, HER2-negative, node-negative breast cancer
    Sestak, Ivana
    Ferree, Sean
    Shemesh, Itay
    Buckingham, Wesley
    Cuzick, Jack
    Dowsett, Mitchell
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [10] Implementation of Oncotype Dx to Guide Chemotherapy Sparing for Women with Postmenopausal N1-3, ER-positive, HER-2-negative Breast Cancer
    Rajakumar, L.
    Glendenning, J.
    Hall, J.
    Burcombe, R.
    McCormick, G.
    Hegarty, G.
    Harper-Wynne, C.
    Brown, B.
    Moss, C.
    Thomas, C.
    Jyothirmayi, R.
    Osman, M.
    Nikiforidis, L.
    [J]. CLINICAL ONCOLOGY, 2024, 36 (04) : E111 - E111
12345